Home › Research › Clinical safety
Palmitoylethanolamide and Luteolin in Brain Aging and Cognitive Decline: Biological Rationale and Current Evidence
Mancinetti F, Boccardi V, Valenza M, Alunno M, Scamosci M, Facchinetti R, Tecchio V, Guazzarini AG et al.. Nutrients, 2026-07-29
Topic: Gut, metabolism and diet
Cognitive decline is closely associated with biological aging and with interconnected processes, including chronic low-grade inflammation, oxidative stress, mitochondrial dysfunction, and cellular senescence. Nutraceutical strategies capable of modulating several of these pathways may represent a complementary approach to supporting cognitive health. This narrative review examines the biological rationale and available evidence regarding palmitoylethanolamide (PEA), luteolin, and their co-ultramicronized formulation (PEA-Lut) in cognitive impairment and dementia. Evidence from mechanistic studies, animal models, observational studies, and clinical trials was considered. PEA is an endogenous N-acylethanolamine with anti-inflammatory and neuroprotective properties, whereas luteolin exerts complementary antioxidant and anti-inflammatory effects. Co-ultramicronization may improve their physicochemical properties and biological activity. Preclinical studies suggest that PEA-Lut may attenuate glial activation, pro-inflammatory signalling, oxidative and nitrosative stress, and amyloid-β-induced cellular injury while supporting neurotrophic signalling and neuronal survival. Preliminary clinical findings have suggested possible benefits in postoperative delirium, stroke rehabilitation, frontotemporal dementia, and other neuroinflammatory conditions. However, human evidence specifically addressing mild cognitive impairment and Alzheimer’s Disease (AD) remains limited, heterogeneous, and largely derived from small or non-randomized studies. PEA-Lut therefore represents a biologically plausible and potentially well-tolerated nutraceutical approach. Adequately powered randomized controlled trials are needed to determine its clinical efficacy, optimal timing and dosage, and long-term safety in individuals at risk of dementia or in the early stages of AD.
Key findings
- Cognitive decline is closely associated with biological aging and with interconnected processes, including chronic low-grade inflammation, oxidative stress, mitochondrial dysfunction, and cellular senescence.
- Preclinical studies suggest that PEA-Lut may attenuate glial activation, pro-inflammatory signalling, oxidative and nitrosative stress, and amyloid-β-induced cellular injury while supporting neurotrophic signalling and neuronal survival.
Study details
- Study designnarrative review
- Evidence strengthHigh
How this study scored 48/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 28 of the 58 points we could judge it on, which is 48 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Nutrients) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | Design recorded as “narrative review”, which our rubric does not rank (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 28 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 28 of the 58 points we could judge it on is 48 out of 100. |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
APA 7th
Mancinetti, F., Boccardi, V., Valenza, M., Alunno, M., Scamosci, M., Facchinetti, R., et al. (2026). Palmitoylethanolamide and Luteolin in Brain Aging and Cognitive Decline: Biological Rationale and Current Evidence. Nutrients. https://doi.org/10.20944/preprints202607.2125.v1
Vancouver
Mancinetti F, Boccardi V, Valenza M, Alunno M, Scamosci M, Facchinetti R, et al. Palmitoylethanolamide and Luteolin in Brain Aging and Cognitive Decline: Biological Rationale and Current Evidence. Nutrients. 2026. doi:10.20944/preprints202607.2125.v1.
BibTeX
@article{mancinetti2026-d4144d2f,
author = {Mancinetti, F. and Boccardi, V. and Valenza, M. and Alunno, M. and Scamosci, M. and Facchinetti, R. and Tecchio, V. and Guazzarini, A. G. and others},
title = {{Palmitoylethanolamide and Luteolin in Brain Aging and Cognitive Decline: Biological Rationale and Current Evidence}},
journal = {Nutrients},
year = {2026},
doi = {10.20944/preprints202607.2125.v1},
url = {https://doi.org/10.20944/preprints202607.2125.v1}
}
Related studies in Clinical safety
Also tagged “curcumin”
117 studies in the library carry the topic tag “curcumin”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 117 tagged studies.